Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 325 versus DIATRIZOATE 60.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 325 versus DIATRIZOATE 60.
CONRAY 325 vs DIATRIZOATE-60
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays by blocking photons, allowing visualization of blood vessels and tissues.
Diatrizoate is an ionic, monomeric, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, enhancing radiographic imaging by attenuating X-ray beams. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
Intravenous: 1.0-2.0 mL/kg (325 mg I/mL) for contrast imaging; maximum total dose 250 mL.
1-2 mL/kg IV bolus up to 150 mL total for contrast-enhanced CT; repeat doses may be given based on imaging needs.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. May be prolonged in renal impairment.
Terminal half-life approximately 1-2 hours in patients with normal renal function. Prolonged in renal impairment (up to 20-30 hours in anuria).
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<5%).
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Negligible biliary or fecal elimination.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent